Indian firm steps in to ensure long-term supply of malaria vaccine

Bharat Biotech will receive manufacturing rights of the RTS,S antigen component from pharmaceutical company GSK. PHOTO: REUTERS
New: Gift this subscriber-only story to your friends and family

KOLKATA - India's vaccine production capacity has come in for praise from various quarters as the world seeks to vaccinate its way out of the Covid-19 pandemic.

Last month, UN Secretary-General António Guterres even described it as "one of the best assets the world has today" as he lauded India for supplying Covid-19 vaccine doses to various nations to support their fight against the coronavirus.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.